Welcome to our dedicated page for Fortress Biotech SEC filings (Ticker: FBIOP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fortress Biotech filings document the biopharmaceutical issuer's preferred and common stock structure, material events, operating results and governance matters. Form 8-K reports identify the Nasdaq-listed common stock and the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, and record events such as subsidiary asset sales, preferred-stock redemptions at subsidiaries, financial-results releases and clinical or regulatory updates.
Proxy filings for Fortress Biotech describe annual meeting voting, director elections, auditor ratification, executive-compensation advisory votes and charter governance matters. The filings also address capital-structure disclosures and material agreements within Fortress's subsidiary-based biopharmaceutical business model.
Fortress Biotech, Inc. is a biopharmaceutical holding and operating company that acquires, develops and monetizes drug assets through a network of subsidiaries and partner companies. It focuses on product revenue, equity stakes, dividends and royalties across dermatology, oncology, rare disease and gene therapy.
As of March 25, 2026, Fortress had 32,202,564 common shares and 3,427,138 shares of 9.375% Series A preferred stock outstanding, with non‑affiliate common equity valued at $43,741,728 as of its most recent second fiscal quarter. The company reports 78 full‑time employees across Fortress and its controlled entities.
Recent transactions reshaped the portfolio. Sun Pharma acquired former subsidiary Checkpoint, giving Fortress $28.0 million in cash plus potential royalties and up to $4.8 million tied to EU approval of UNLOXCYT. Cyprium’s Menkes disease therapy ZYCUBO won FDA approval, with up to $128 million in potential sales milestones and tiered royalties, and Cyprium sold its priority review voucher for $205 million. Additional upside comes from Journey’s launch of EMROSI for rosacea, an exclusive license for Avenue’s ATX‑04 in lysosomal storage diseases, Urica’s equity and royalty position in Crystalys’ Phase 3 gout program, and multiple late‑stage and mid‑stage programs in CMV vaccines, GBM CAR‑T, and other rare and neurological diseases.
Fortress Biotech reported that its majority-owned subsidiary Cyprium Therapeutics has closed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds under a previously disclosed asset purchase agreement. In connection with the transaction, Cyprium redeemed all outstanding shares of its 9.375% Perpetual Preferred Stock.
Fortress, which owns 80.4% of Cyprium’s outstanding common stock on an as-converted basis, expects to receive at least $100.0 million from Cyprium through potential future dividends and intercompany agreements, including intercompany debt, interest and accrued expenses. Cyprium must pay 20% of the PRV sale proceeds to an institute of the National Institutes of Health and also remains eligible to receive tiered royalties on net sales of ZYCUBO and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics.
Fortress Biotech’s chairman, president and CEO Lindsay A. Rosenwald filed Amendment No. 5 to his Schedule 13D, reporting beneficial ownership of 6,917,715 shares of common stock, or 20.7% of the company, based on 31,037,937 shares outstanding as reported in a December 2025 prospectus supplement.
The position includes 4,050,765 issued shares held directly, 475,424 unvested restricted shares subject to repurchase, 2,330,874 shares underlying currently exercisable warrants, and smaller holdings through Paramount Biosciences, LLC and Capretti Grandi LLC over which he has voting and dispositive control. It excludes 96,919 shares held by family trusts where he lacks such control.
The amendment reflects equity grants of 454,153 shares on January 1, 2025 and 475,424 shares on March 18, 2026 under Fortress Biotech’s Long Term Incentive Plan, awarded after he achieved 100% of goals set by the compensation committee. Rosenwald states he has no present plans for major corporate actions or additional acquisitions or dispositions beyond this compensation-related ownership.
ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. reported that President, CEO & Chairman Lindsay A. Rosenwald received a grant of 475,424 shares of common stock on March 18, 2026. These are restricted shares awarded under the company’s Long-Term Incentive Plan, rather than an open-market purchase.
Following this equity award, Rosenwald directly holds 4,586,841 shares of Fortress Biotech common stock. The transaction reflects stock-based compensation that further ties the executive’s interests to the company’s long-term performance.
WEISS MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. insider Michael S. Weiss, the Executive Vice Chairman, received a grant of 475,424 shares of common stock on March 18, 2026. These restricted shares were awarded under the company’s Long-Term Incentive Plan and increased his direct holdings to 2,276,562 shares. This is a compensation-related equity award rather than an open-market purchase or sale.
Fortress Biotech’s majority-owned subsidiary Cyprium Therapeutics agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for $205 million in cash, payable at closing. The voucher was granted after ZYCUBO was approved to treat Menkes disease in pediatric patients.
Fortress owns 80.4% of Cyprium’s common stock and expects to receive at least $100 million over time from Cyprium through dividends and intercompany arrangements, subject to closing, taxes, required payments to a National Institutes of Health institute, Cyprium’s preferred stock redemption and other obligations. Fortress also amended its Oaktree credit agreement to ease several financial covenants after the PRV sale and to apply $10 million of proceeds, plus interest and a yield protection premium, to mandatory loan prepayment.
Fortress Biotech, Inc. furnished a press release that provides a corporate update and announces its financial results for the quarter ended June 30, 2025.
The press release is included as Exhibit 99.1 and is furnished, not filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.